Development of Dual ARV-825 and Nintedanib-Loaded PEGylated Nano-Liposomes for Synergistic Efficacy in Vemurafnib-Resistant Melanoma

Development of Dual ARV-825 and Nintedanib-Loaded PEGylated Nano-Liposomes for Synergistic Efficacy in Vemurafnib-Resistant Melanoma

A novel treatment strategy by co-targeting c-Myc and tumor stroma was explored in vemurafenib-resistant melanoma. BRD4 proteolysis targeting chimera (ARV-825) and nintedanib co-loaded PEGylated nanoliposomes (ARNIPL) were developed to incorporate a synergistic cytotoxic ratio. Both the molecules hav...

Description complète

Détails bibliographiques
Auteurs principaux: Yige Fu, Aishwarya Saraswat, Zenghui Wei, Manas Yogendra Agrawal, Vikas V. Dukhande, Sandra E. Reznik, Ketan Patel
Format: Article
Langue:English
Publié: MDPI AG 2021-07-01
Collection:Pharmaceutics
Sujets:
ARV-825
proteolysis targeting chimera
nintedanib
vemurafenib-resistant melanoma
PEGylated nanoliposomes
synergistic interaction
Accès en ligne:https://www.mdpi.com/1999-4923/13/7/1005

Internet

https://www.mdpi.com/1999-4923/13/7/1005

Documents similaires